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Purpose: Our goal was to identify candidate polymorphisms that
could influence overall survival (OS) in advanced non-small cell
lung cancer (NSCLC) patients treated with carboplatin (CBDCA)
and paclitaxel (PTX).
Methods: Chemotherapy-naïve stage IIIB or IV NSCLC patients
treated with CBDCA (area under the curve  6 mg/mL/min) and
PTX (200 mg/m2, 3-hour period) were eligible for this study. The
DNA samples were extracted from peripheral blood mononuclear
cells before treatment, and genotypes at approximately 110,000
gene-centric single-nucleotide polymorphisms (SNPs) were ob-
tained by Illumina’s Sentrix Human-1 Genotyping BeadChip. Sta-
tistical analyses were performed by the log-rank test and Cox
proportional hazards model.
Results: From July 2002 to May 2004, 105 patients received a total
of 308 cycles of treatment. The median survival time (MST) of 105
patients was 17.1 months. In the genome-wide association study,
three SNPs were associated significantly with shortened OS after
multiple comparison adjustment: rs1656402 in the EIF4E2 gene
(MST was 18.0 and 7.7 months for AG [n 50] AA [n 40] and
GG [n 15], respectively; p 8.4 108), rs1209950 in the ETS2
gene (MST  17.7 and 7.4 months for CC [n  94] and CT [n 
11]  TT [n  0]; p  2.8  107), and rs9981861 in the DSCAM
gene (MST 17.1 and 3.8 months for AA [n 75] AG [n 26]
and GG [n  4]; p  3.5  106).
Conclusion: Three SNPs were identified as new prognostic biomar-
ker candidates for advanced NSCLC treated with CBDCA and PTX.
The agnostic genome-wide association study may unveil unexplored
molecular pathways associated with the drug response, but our
findings should be replicated by other investigators.
Key Words: Advanced non-small lung cancer, Carboplatin,
Paclitaxel, Genome-wide association study, Single-nucleotide
polymorphisms.
(J Thorac Oncol. 2011;6: 132–138)
Lung cancer is the leading cause of cancer death in Japanand worldwide for both men and women.1 Non-small cell
lung cancer (NSCLC) accounts for approximately 85% of
lung cancer cases. Several third-generation agents are avail-
able for the treatment of NSCLC, including docetaxel, pac-
litaxel (PTX), gemcitabine, and vinorelbine, and the combi-
nation of one of these agents with a platinum compound has
been considered the standard treatment option for advanced
NSCLC.2–9
Despite these advances, survival prospects still remain
disappointingly low for most patients. To seek further improve-
ments in response rate and survival time, the conventional
treatment approach to NSCLC is beginning to shift toward the
application of specific strategies and techniques, such as phar-
macogenomics to tailor treatment to individual patients.10,11
To identify the clinical predictors of outcome, it is
critically important to observe individual differences in drug
response and the role of genetic polymorphisms that are
relevant to the pathways of drug metabolism and/or the
biology of drug responses. However, genetic polymorphisms
that are associated with overall survival (OS) or antitumor
effect have not yet been fully elucidated.
With this as background, this prospective study em-
ployed a genome-wide association study (GWAS) to identify
candidate polymorphisms that could influence OS in ad-
vanced NSCLC patients treated with carboplatin (CBDCA)
and PTX. Possible associations with toxicities and pharma-
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cokinetic (PK) parameters were also tested to complement
our previous candidate gene approach focusing on CYP3A412
and CYP2C8.13
PATIENTS AND METHODS
Patient Recruitment and Treatment Schedule
Patients with histologically and/or cytologically docu-
mented NSCLC were eligible for participation in the study
and treated with CBDCA and PTX at the National Cancer
Center Hospital and National Cancer Center Hospital East.
Each patient had to meet the following criteria: clinical stage
IIIB or IV, no prior chemotherapy, no prior surgery and/or
radiotherapy for the primary site, age older than 20 years, and
Eastern Cooperative Oncology Group performance status14
between 0 and 2. This study was approved by the Ethics
Review Committees of the National Cancer Center and Na-
tional Institutes of Health Sciences, and written informed
consent was obtained from all patients before study entry.
One hundred five patients received 200 mg/m2 of PTX
(Bristol-Myers K.K., Tokyo, Japan) over a 3-hour period
followed by carboplatin at a dose calculated to produce an
area under the concentration time curve of 6.0 mg/mL/min on
day 1, with the cycle being repeated every 3 weeks. In
addition, to prevent hypersensitivity reactions, all patients
received short-term premedication including dexamethasone,
ranitidine, and an antiallergic agent (diphenhydramine or
chlorpheniramine maleate).
Monitoring, Response and Toxicity Evaluation,
and Follow-Up
A complete medical history and data on physical ex-
aminations were recorded before the CBDCA and PTX com-
bination therapy. Complete blood cell and platelet counts as
well as blood chemistry were measured once a week during
the first 2 months of the treatment. Response was evaluated
according to the Response Evaluation Criteria in Solid Tu-
mors (RECIST), except that tumor markers were excluded
from the criteria. Toxicity grading criteria in National Cancer
Institute Common Toxicity Criteria Version 2.0 were used to
evaluate toxicity. Patients were followed by direct evaluation
or resident registration until death or up to 5 years after
treatment. OS was calculated from the date of patient enroll-
ment in this study to the date of death or the last follow-up.
Pharmacokinetic Sampling and Analysis
For PTX PK analysis, 5 ml of heparinized blood was
sampled before the first PTX administration and at 0, 1, 3,
and 9 hours after the termination of the infusion. The area
under the curve (AUC) and clearance (CL m2) were calcu-
lated by a curve fitting method using the model of two
compartments with constant infusion using WinNonlin ver.
3.3 (Pharsight Corporation, Mountain View, CA). The PK
data were used in our previous pharmacogenetic analyses.12,13
DNA Extraction and Genotyping
Whole blood was collected from patients at the time of
enrollment, and DNA was extracted from peripheral lympho-
cytes using a proteinase-K phenol chloroform method or
Qiagen FlexiGene DNA isolation kit (QIAGEN Inc., Valen-
cia, CA). All samples were assayed with the Illumina In-
finium Human-1 BeadChip (Illumina Inc., San Diego, CA),
which assays 109,365 gene-centric single-nucleotide poly-
morphisms (SNPs). If a genotyping call rate on all SNPs was
found to be less than 95%, the sample was excluded from the
analysis.
Statistical Analysis
As a quality control for genotyping, Hardy-Weinberg
equilibrium testing was applied. To estimate the association
between OS and genotypes, hazard ratios (HRs) and 95%
confidence intervals were calculated using univariate or mul-
tivariate Cox proportional hazards models15,16 and assessed
using the log-rank test. Survival curves were drawn using the
Kaplan-Meier method.14 Statistical significance level was set
to 0.05, two sided, after Holm’s adjustment for a multiple
testing.17 All statistical analyses were performed with the use
of SAS software, version 9.1.3 (SAS Institute Inc., Cary,
NC). All statistical analyses were planned before the study.
RESULTS
Patient Characteristics, Survival, Response, and
Toxicity
From July 2002 to May 2004, 239 patients treated with
PTX were enrolled. Among them, 110 chemotherapy-naïve
advanced NSCLC patients treated with CBDCA (AUC  6
mg/mL/min) and PTX (200 mg/m2, 3-hour period) were
eligible in this study, but five patients were excluded from the
analysis because genotyping data were not available. Their
characteristics are shown in Table 1. All patients were fol-
lowed up for more than 2.5 years, and the median follow-up
time among censored observations was 38 months (range,
27–46 months), with 89 patients deceased (85%) as of
November 2006. The median survival time (MST) of the 105
patients was 17.1 months (95% confidence interval: 15.0–
18.7) (Figure 1). The 1- and 3-year survival probabilities
were 68% and 16%, respectively.
Of the 105 patients, changes in tumor measurements
were partial response in 43 (41%) patients, stable disease in
47 (45%), progressive disease in 11 (10%), and not evaluated
in 4 (4%). There were no cases with a complete response.
All patients were evaluated for toxicity. Hematologic
toxicity and nonhematologic toxicity are summarized in Ta-
ble 2. Grade 3 or 4 nonhematologic toxicity occurred in 15
TABLE 1. Patient Characteristics
Assessable patients 105
Gender (male/female) 76/29
Age, median (range) 61 (29–80)
PS (0/1/2) 20/82/3
Stage (IIIB/IV) 46/59




Journal of Thoracic Oncology • Volume 6, Number 1, January 2011 OS of Advanced NSCLC Patients
Copyright © 2010 by the International Association for the Study of Lung Cancer 133
(14%) patients, suggesting that nonhematologic toxicity was
generally mild; but grade 4 motor neuropathy occurred in one
patient and grade 4 diarrhea occurred in another. On the other
hand, grade 3 or 4 hematologic toxicity occurred in 57 (53%)
patients. Grade 4 neutropenia occurred in 18 (17%) patients.
Febrile neutropenia (grade 3) occurred in five patients.
Effects of Patients’ Background on Overall
Survival
The effects of patients’ background on OS were ana-
lyzed as summarized in Table 3. The effects of gender,
Eastern Cooperative Oncology Group performance status,
and tumor response showed significant associations with OS,
but age, stage, and number of cycles did not show a signifi-
cant association.
Pharmacogenomic Analyses
Table 4 lists 10 SNPs, showing the least p values for
log-rank test. The following three SNPs were associated
significantly with shortened OS after multiple comparison
adjustment: rs1656402 in the EIF4E2 gene (MST for AG
[n  50]  AA [n  40] and GG [n  15] were 18.0 and 7.7
months, respectively; p  8.4  108, HR  4.22 [2.32–
7.66]), rs1209950 in the ETS2 gene (MST for CC [n  94]
and CT [n  11]  TT [n  0] were 17.7 and 7.4 months,
respectively; p  2.8  107, HR  4.96 [2.52–9.76]), and
rs9981861 in the DSCAM gene (MST for GG [n 75] AG
[n  26] and AA [n  4] were 17.1 and 3.8 months,
respectively; p  3.5  106, HR  16.1 [5.38–51.2]). In
Figure 2, the Kaplan-Meier plots were drawn with subjects
stratified into subgroups according to each significant polymor-
phism in either dominant or recessive model. Two (rs1656402
and rs9981861) of these significant SNPs were associated with
tumor response and AUC 6-,C3-p-dihydroxy-PTX as shown
FIGURE 1. Kaplan-Meier plot for overall
survival.
TABLE 2. Incidence of Hematologic and Nonhematologic
Toxicities After the First Cycle
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 Total
Leukopenia 40 34 9 0 101
Neutropenia 8 22 39 18 105
Anemia 73 16 2 0 105
Thrombocytopenia 16 3 0 0 102
Febrile neutropenia 0 0 5 0 105
Nausea 7 3 0 0 105
Vomiting 8 4 3 0 105
Diarrhea 5 6 0 1 105
Arthralgia 58 12 2 0 105
Myalgia 47 10 1 0 105
Hyperbilirubinemia 33 10 0 0 105
AST (GOT) increase 38 1 0 0 105
ALT (GPT) increase 38 3 1 0 105
ALP increase 32 5 0 0 105
Neuropathy, sensory 65 6 1 0 105
Neuropathy, motor 1 0 0 1 105
AST, aspartate transaminase; GOT, glutamic oxaloacetic transaminase; ALT,
alanine aminotransferase; GPT, glutamate pyruvate transaminase; ALP, alkaline phos-
phatase.








65 vs. 65 1.12 0.72–1.71 0.61
Gender
Male vs. female 2.06 1.26–3.39 0.0039
PS
2 vs. 0–1 7.68 2.28–25.8 0.0010
Stage
IV vs. IIIB 1.19 0.78–1.83 0.40
No. of cycles 0.92 0.74–1.13 0.42
Tumor response
PR vs. PD 0.199 0.098–0.403 .0001
NC vs. PD 0.216 0.108–0.434 .0001
CI, confidence interval; HR, hazard ratio; PR, partial response; PD, progressive
disease; NC, no change.
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in Supplementary Tables 1 (http://links.lww.com/JTO/A43) and
2 (http://links.lww.com/IGC/A24), respectively.
The following PK parameters were measured in this
study: AUC PTX (h*/g/mL), AUC 6--hydroxy-PTX (6--
OH-PTX) (h/g/ml), AUC C3-p-hydroxy-PTX (3-p-OH-PTX)
(h*/g/mL), AUC 6-,C3-p-dihydroxy-PTX (diOH-PTX) (h*/
g/mL), AUC Cremophor EL (l*/h/mL), CL PTX (L/h/m2).
However, no significant association was detected between the
PK parameters and the SNPs by a multiple testing correction
(data not shown). For reference, we showed the results of
association between top 10 SNPs and PK parameters in Supple-
mentary Table 2. This GWAS neither detected a statistically
significant association with any of the grade 3/4 adverse reac-
tions (data not shown), probably due to their low incidence,
except for neutropenia (Table 2).
DISCUSSION
Cytotoxic chemotherapy continues to be the mainstay
for initial treatment of patients with advanced NSCLC. Indi-
vidualizing chemotherapy to deliver the most active and least
toxic agent to each patient could provide an important im-
provement in patient care.11 Previous pharmacogenetic
studies have identified biomarkers for survival of patients
with advanced NSCLC treated with platinum-based che-
motherapy.18–22 Among these are the XRCC1, XRCC3, and
XPD genes, which play an important role in DNA re-
pair.23–28 Similar to previous studies of platinum-based
chemotherapy, Gurubhagavatula et al.18 observed a trend
toward decreased survival for patients with variant XPD or
XRCC1 genotype and improved survival for patients with
variant XRCC3 genotype.
These genetic polymorphisms were identified by can-
didate gene approach, which relies on an a priori selection of
small numbers of candidate genes based on the existing
information or hypothesis. Although successful in several
examples, this candidate gene approach may not be able to
capture all the genetic factors, which influence a drug re-
sponse in a complex interplay with multiple unknown as well
TABLE 4. Ten SNPs Associated with OS in GWAS




MST (95% CI) HR (95% CI) pa pb pcGene Symbol Genotype Total Events
2 rs1656402 EIF4E2 AA 0.145 40 37 15.6 (13.5–17.0) Ref 8.4  108 4.5  107 0.0046
AG 0.461 50 37 24.4 (18.6–30.3) 0.42 (0.26–0.67)
GG 0.393 15 15 7.69 (5.95–12.7) 2.73 (1.46–5.10)
21 rs1209950 ETS2 CC 0.938 94 78 17.6 (16.2–21.4) Ref 2.8  107 6.5  105 0.015
CT 0.059 11 11 7.39 (4.86–10.2) 4.96 (2.52–9.76)
TT 0.002 — — — NA
21 rs9981861 DSCAM AA 0.652 75 61 17.8 (15.3–21.4) Ref 3.5  106 9.2  107 0.050
AG 0.314 26 24 16.5 (2.14–18.1) 1.33 (0.82–2.15)
GG 0.034 4 4 3.78 (2.14–7.69) 18.0 (5.78–56.2)
2 rs10496036 RTN4 GG 0.701 84 70 17.6 (15.9–21.4) Ref 2.4  105 0.00063 1.00
AG 0.270 18 2 14.1 (9.63–19.6) 1.52 (0.87–2.62)
AA 0.030 3 0 4.30 (2.43–5.95) 22.2 (5.72–86.2)
6 rs1547633 GG 0.678 69 60 16.9 (13.6–18.3) Ref 2.3  105 7.7  106 1.00
GT 0.283 33 26 21.4 (16.2–27.0) 0.76 (0.48–1.21)
TT 0.039 3 3 3.58 (3.02–4.30) 29.7 (6.47–136)
6 rs1570070 IGF2R GG 0.553 66 57 18.2 (15.8–21.4) Ref 2.2  105 0.00010 1.00
GA 0.388 33 27 16.4 (11.4–17.7) 1.01 (0.63–1.62)
AA 0.059 4 4 4.67 (2.17–7.39) 10.5 (3.85–28.9)
7 rs2711095 GG 0.655 70 59 17.3 (15.9–19.6) Ref 2.3  105 5.0  105 1.00
AG 0.303 30 25 17.3 (11.7–27.0) 1.33 (0.88–2.00)
AA 0.042 5 5 5.39 (1.25–9.63) 10.2 (3.8–27.1)
16 rs4313828 CNTNAP4 AA 0.947 99 83 17.4 (15.8–20.4) Ref 2.2  105 8.2  105 1.00
AG 0.050 6 6 7.51 (3.22–9.92) 7.12 (2.87–17.6)
GG 0.003 — — — NA
6 rs894817 IGF2R AA 0.560 65 56 18.3 (15.8–22.3) Ref 2.8  105 0.00012 1.00
AG 0.379 36 29 16.2 (10.2–17.7) 1.09 (0.69–1.71)
GG 0.061 4 4 4.67 (2.17–7.39) 14.3 (4.57–44.9)
7 rs959494 SCIN AA 0.659 70 56 17.5 (15.9–21.4) Ref 3.1  105 0.00043 1.00
AG 0.299 30 28 16.0 (8.44–20.3) 1.53 (0.97–2.42)
GG 0.042 4 4 5.08 (2.43–9.07) 12.0 (3.97–36.7)
a p values were calculated by univariate Cox proportional hazards model.
b p values were calculated by multivariate Cox proportional hazards model including gender and PS as covariates.
c p values were adjusted for multiple testing by using the Holm’s method.
MST, median survival time; CI, confidence interval; HR, hazard ratio.
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as known factors such as disease phenotypes, genetic factors,
and the variability in drug target response. GWAS, which
makes no assumptions about the genomic location of the
causal variants but surveys the whole genome,29,30 is ex-
pected to complement the candidate gene approach. Accord-
ing to our findings from a gene-centric GWAS, three poly-
FIGURE 2. Overall survival stratified for the
single-nucleotide polymorphism genotype.
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morphisms were associated with shortened OS in advanced
NSCLC with CBDCA and PTX. The three SNPs have not
been previously investigated for an association with NSCLC
risk or drug response. On the other hand, the SNPs implicated
in the prognosis of NSCLC by the previous candidate gene
approach18 were not detected in the GWAS, because the
Human-1 BeadChip does not harbor the identical SNPs ana-
lyzed before and/or their p values were not sufficiently small
in the context of the genome scan.
The first candidate SNP for the OS association,
rs1656402, is in the third intron of the gene, EIF4E2, encod-
ing for the translational factor eukaryotic initiation factor 4E,
which is a central component in the initiation and regulation
of translation in eukaryotic cells. Through its interaction with
the 5 cap structure of mRNA, eIF4E functions to recruit
mRNAs to the ribosome.31–34 Prototypical eIF4E-2 is ex-
pressed ubiquitously,33,35 but in metastatic tumors, its expres-
sion was increased,36 suggesting that eIF4E-2 plays an active
role in the prognosis of NSCLC.
The second candidate SNP is located at the 4321 bp
upstream of the ETS2 gene. The Ets family of transcription
factors includes important downstream targets in cellular
transformation. For instance, alteration of Ets activity has
been found to reverse the transformed phenotype of ras-
transfected mouse fibroblasts and of several human tumor cell
lines. It has been reported that Ets factor activity can strongly
influence the transformed and invasive phenotype of a human
prostate tumor cell line.37
The third candidate rs9981861 is in the 31st intron of
the 33-exon DSCAM gene, which encodes Down syndrome
cell adhesion molecule, a member of the immunoglobulin
superfamily. The gene was cloned from the Down syndrome
region on chromosome 21q22 and found to be expressed
widely in the developing nervous system.38 Mouse DSCAM
has been shown to mediate arborization of neurite processes
and spacing of neuronal cell bodies.39,40 Expression of the
DSCAM gene has been upregulated in small cell lung cancer
compared with NSCLC.41
Because a GWAS is based on a linkage disequilibrium
(LD) mapping of a disease locus by use of SNPs as markers,
the particular SNPs per se identified in this study may not be
functionally responsible for the observed effect on survival
time. In fact, LD maps drawn by the HapMap data around the
three SNPs indicate that at least the SNPs of the EIF4E2 and
ETS2 genes are embedded in extended LD blocks (Supple-
mentary Figure 1, http://links.lww.com/IGC/A25); it may be
then difficult to narrow down the regions of interest further
for these SNPs by statistical genetics alone, at least in the
Asian population.
In summary, a hypothesis-free GWAS detected previ-
ously unrecognized associations between polymorphisms of
the three genes and shortened OS in advanced NSCLC treated
with CBDCA and PTX. Additionally, these three SNPs on the
three genes were significant after a multiple testing adjust-
ment. In considering a multiple testing problem, we assume
the existence of about 10,000 linkage disequilibrium blocks
within 100,000 gene-centric SNPs, which are concentrated in
about 2% of the human genome (i.e., average interval of two
SNPs is 600 bp). It follows that the p value cutoff is set at
5.0  106 if the Bonferroni correction is applied. However,
in the first screening, such correction for a multiple testing is
often too conservative, failing to detect many drug-response
SNPs; therefore, we showed top 10 SNPs in Table 4. In
addition, to facilitate the second screening or replication
studies by other investigators, statistics of association be-
tween OS, PK parameters, toxicity, and all SNPs analyzed in
this study are available at Genome Medicine Database of
Japan (http://gemdbj.nibio.go.jp).
The ultimate goal of this work is better clinical man-
agement of patients after the assessment of genotype risk on
OS. To this end, however, we need to identify genetic
polymorphisms that can differentiate patients’ response and
outcome to different chemotherapeutic agents. Although our
work may contribute as the first step to establish such a
predictive factor, especially the survival-related SNPs that
also influence pharmacokinetics, the current single-arm pro-
spective study does not provide definite evidence of pharma-
cogenomic profiling for a platinum-based chemotherapy.
Several targeted therapies for NSCLC are in clinical devel-
opment, and it is hoped that this line of pharmacogenetic
studies will eventually help clinicians to choose platinum or
nonplatinum doublets as the first-line regimen, for instance.
Further studies of NSCLC would stratify patients according
to the SNP status to tailor treatment to individual patients.
The results of a single association study should be validated
by independent studies by other investigators as well as
biologic functional analyses.
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